John Sonnier


William Blair Tweaks Estimates For Gilead Sciences, Inc. (GILD) Ahead Of Q1 Print

As the earnings season kicks off for the biotechnology sector, William Blair analyst John Sonnier outlined updated earnings per share (EPS) estimates for Gilead …

William Blair Sets Bullish Expectations On Two Biotech Giants: Gilead Sciences, Inc. (GILD) and Exelixis, Inc. (EXEL)

As he previews fourth-quarter results for these two biotech giants, William Blair analyst John Sonnier is setting positive expectations on Gilead Sciences, Inc. (NASDAQ:GILD) …

William Blair Positive on Gilead Sciences, Inc. (GILD) Following Data Releases

Last Thursday, Gilead Sciences, Inc. (NASDAQ:GILD) announced Phase III POLARIS topline data with sofosbuvir (nucleotide polymerase inhibitor)/velpatasvir (NS5A inhibitor)/voxilaprevir (protease inhibitor) in treatment-naïve …

Analysts Weigh in on Two Collapsing Biotech Stocks: Threshold Pharmaceuticals, Inc. (THLD) and Alcobra Ltd (ADHD)

The biotech world is experiencing volatility in the midst of a drug development discontinuation for Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) and word from the FDA to …

William Blair Dives in on Exelixis, Inc. (EXEL) Ahead of Phase II CABOSUN Data

William Blair analyst John Sonnier is out with a research report on Exelixis, Inc. (NASDAQ:EXEL) as the biotech company’s shares have been shooting …

William Blair Remains Positive on Bristol-Myers Squibb Co (BMY) in Wake of Disappointing Phase III Failure

Friday morning before market open, Bristol-Myers Squibb Co (NYSE:BMY) came to terms with the failure of its Phase III CheckMate-026 trial evaluating Opdivo …

William Blair Weighs In On Gilead Sciences, Inc. Following Positive Top-Line SOF/VEL Results

William Blair’s healthcare analyst John Sonnier weighed in with a favorable report on Gilead Sciences, Inc.  (NASDAQ:GILD), after the company announced positive clinical data featuring the company’s next-generation, …

William Blair Offers Commentary On Agenus Inc (AGEN) Following $115 Million Royalty Deal

William Blair’s healthcare analyst John Sonnier weighed in with a few insights on Agenus Inc (NASDAQ:AGEN), as the company yesterday announced a transaction with an investor group …

William Blair’s Best Picks Amid the Unstable Market: Celgene Corporation (CELG), Google Inc (GOOGL), Palo Alto Networks, Inc. (PANW)

In light of the recent market volatility last week, William Blair issued a note to investors on August 27 highlighting the firm’s top …

William Blair Weighs In on Exelixis, Inc. Following Cobimetinib Approval in Switzerland

William Blair’s healthcare analyst John Sonnier weighed in today with a few insights on Exelixis, Inc. (NASDAQ:EXEL), after the biopharmaceutical company announced that the the Swiss authority which …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts